Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

By Laurent Castéra, J. Vergniol, J. Foucher, B. le Bail, E. Chanteloup, M. Haaser, M. Darriet, P. Couzigou, V. de Lédinghen. Gastroenterology, 2005

2,856 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “The two index studies suggesting the interest of TE in the assessment of liver fibrosis have been conducted in patients with chronic hepatitis C [126,127].”
EASL recommendations on treatment of hepatitis C - Final update of the series. (2020, background): “The combination of blood biomarkers or the combination of liver stiffness measurement and a blood test improve accuracy.(102,103) Notably, non-invasive tools should not be used to assess fibrosis stage after therapy, as they are unreliable in this setting.”
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. (2005, background): “APRI had lower accuracy (AUC of 0.74) for determining more subtle grades of fibrosis (portal fibrosis with rare septae) compared with the Hepascore (AUC of 0.82–0.85) (30, 31 ).”
Shear Wave Spectroscopy for In Vivo Quantification of Human Soft Tissues Visco-Elasticity (2009, background): “elasticity images provide high contrast for many clinical applications such as breast cancer [4]–[13] or liver fibrosis staging [14]–[17].”